{"gene":"FGF21","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2013,"finding":"Adiponectin is a downstream effector of FGF21 in mediating its systemic insulin-sensitizing effects. FGF21 treatment enhanced adiponectin expression and secretion in adipocytes, raising serum adiponectin. Adiponectin knockout mice were refractory to FGF21-mediated alleviation of hyperglycemia, hypertriglyceridemia, insulin resistance, and hepatic steatosis, while FGF21-mediated ERK1/2 activation in adipose tissue remained intact.","method":"Adiponectin knockout mouse model, FGF21 administration, serum/tissue metabolic assays, Western blotting for insulin signaling","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal metabolic readouts, clearly dissects FGF21-adiponectin axis from direct ERK signaling","pmids":["23663741"],"is_preprint":false},{"year":2011,"finding":"Brown adipose tissue (BAT) is a source of circulating FGF21 upon thermogenic activation. Norepinephrine acts via β-adrenergic/cAMP/PKA/p38 MAPK signaling to induce FGF21 gene transcription, with ATF2 binding the FGF21 promoter as the mediating transcription factor. Cold exposure in rats caused direct FGF21 release from BAT measured by arteriovenous differences.","method":"Arteriovenous difference measurements across interscapular BAT, blood flow measurement, β-adrenergic pharmacology, p38 MAPK inhibitors, ATF2 chromatin binding assays, in vivo cold exposure","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including direct in vivo AV-difference, pharmacological pathway dissection, and promoter binding","pmids":["21317437"],"is_preprint":false},{"year":2008,"finding":"Skeletal muscle is a source of FGF21, and FGF21 expression and secretion in muscle are regulated by the PI3K/Akt1 signaling pathway. Akt1 transgenic mice showed elevated muscle and serum FGF21; insulin and LY294002 regulated FGF21 in cultured muscle cells.","method":"Akt1 skeletal muscle-specific transgenic mice, PI3K inhibitor (LY294002), cultured myocytes, serum FGF21 measurement, protein/mRNA expression","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic model plus pharmacological inhibition, single lab","pmids":["18948104"],"is_preprint":false},{"year":2015,"finding":"FGF21 reduces sweet preference and alcohol preference via its co-receptor β-Klotho in the central nervous system, and correlates with reduced dopamine concentrations in the nucleus accumbens.","method":"FGF21 administration in mice and cynomolgus monkeys, CNS-specific β-Klotho knockout mice, dopamine measurement in nucleus accumbens, preference behavioral assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — CNS-specific genetic knockout plus pharmacological intervention across two species with neurochemical readout","pmids":["26724861"],"is_preprint":false},{"year":2017,"finding":"FGF21 acts as a secretagogue in pancreatic acinar cells, stimulating digestive enzyme secretion through an autocrine/paracrine mechanism requiring FGFR–β-Klotho signaling. FGF21 triggers intracellular calcium release via PLC-IP3R signaling. FGF21-deficient mice accumulate zymogen granules and show pancreatic ER stress; acinar-specific β-Klotho deletion also causes granule accumulation and prevents FGF21-stimulated secretion.","method":"FGF21 and β-Klotho knockout mice, acinar cell-specific β-Klotho deletion, recombinant FGF21 rescue, calcium imaging, PLC-IP3R pathway pharmacology, zymogen granule quantification","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reconstitution with recombinant FGF21, multiple genetic models, defined signaling mechanism via PLC-IP3R","pmids":["28089565"],"is_preprint":false},{"year":2019,"finding":"FGF21 signaling in the brain via β-Klotho (KLB) is required for the adaptive physiological response to dietary protein restriction, including shifts in macronutrient preference toward protein, increased energy expenditure, and glucose homeostasis. Brain-specific KLB deletion or whole-body FGF21 deletion abolishes these responses.","method":"Brain-specific KLB knockout mice, whole-body FGF21 knockout mice, dietary protein restriction protocols, metabolic phenotyping, food preference assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent genetic models (brain-specific KLB KO and FGF21 global KO) with multiple orthogonal metabolic readouts","pmids":["31167139"],"is_preprint":false},{"year":2018,"finding":"HRD1-ERAD E3 ubiquitin ligase controls FGF21 production by catalyzing polyubiquitin conjugation onto the ER-tethered transcription factor CREBH at lysine 294, targeting it for proteasomal degradation. Liver-specific HRD1 deletion prevents FGF21 suppression during refeeding, phenocopying FGF21 gain-of-function mice.","method":"Liver-specific HRD1 knockout mice, polyubiquitination assay, site-specific mutagenesis (K294), proteasome inhibition, refeeding experiments, serum FGF21 measurement","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro ubiquitination assay with mutagenesis, genetic KO model, and mechanistic pathway identification","pmids":["30389664"],"is_preprint":false},{"year":2019,"finding":"Liver-derived FGF21 (not adipose-derived) enters circulation during acute cold exposure and is critical for thermoregulation. Central FGF21 signaling (via CNS β-Klotho) is necessary for maximal sympathetic drive to BAT to maintain thermoregulation; direct FGF21 signaling to adipose tissue is dispensable.","method":"Liver-specific FGF21 KO mice, adipose-specific FGF21 KO mice, adipose-specific KLB KO mice, pharmacological CNS FGF21 blockade, cold exposure studies, body temperature monitoring","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple tissue-specific genetic models dissecting tissue source and site of action, replicated across approaches","pmids":["30679672"],"is_preprint":false},{"year":2014,"finding":"FGF21 expression and secretion in muscle cells is controlled by MyoD as a major transcriptional regulator, and is induced by mitochondrial dysfunction via increased ROS → p38 MAPK → ATF2 binding to the proximal FGF21 promoter. MyoD is required for mitochondrial dysfunction-induced FGF21 expression in myogenic cells.","method":"Respiratory chain/OXPHOS inhibitors in cultured muscle cells, MyoD knockdown, ROS measurement, p38 MAPK inhibition, ATF2 promoter binding assay, FGF21 mRNA/protein/secretion assays","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — promoter binding assay, pharmacological pathway dissection, transcription factor knockdown, single lab but multiple orthogonal methods","pmids":["25055037"],"is_preprint":false},{"year":2015,"finding":"FGF21-mediated improvements in glucose clearance require UCP1. While FGF21 can lower body weight in both wild-type and Ucp1-knockout mice, rapid clearance of a glucose challenge by FGF21 is defective in Ucp1-KO mice, implicating UCP1-dependent thermogenesis in BAT as a mechanism for FGF21-driven glucose disposal.","method":"Ucp1 knockout mice, FGF21 administration, glucose tolerance tests, BAT temperature measurement, UCP1 protein quantification","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with pharmacological FGF21 treatment, clear dissection of weight-loss vs glucose-clearance effects","pmids":["26586424"],"is_preprint":false},{"year":2017,"finding":"Dietary protein restriction increases lifespan, reduces frailty, and improves metabolic health in mice in an FGF21-dependent manner. FGF21-knockout mice fail to exhibit these metabolic responses to protein restriction and show accelerated aging phenotypes.","method":"FGF21 global knockout mice, long-term dietary protein restriction, lifespan measurement, frailty assessment, metabolic phenotyping","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with lifespan and multiple metabolic readouts, replicated in a subsequent Nature Communications paper (35393401)","pmids":["28811495","35393401"],"is_preprint":false},{"year":2018,"finding":"The C-terminal sequence of FGF21 defines its binding to β-Klotho (KLB) and is the primary determinant of receptor activation. C-terminal FGF21 peptides potently inhibit FGF21/KLB-mediated signaling. Key residues are highly conserved with FGF19, and substituting native FGF21 C-terminal sequence with an optimized high-affinity peptide generates a super-agonist with enhanced metabolic efficacy in obese mice.","method":"In vitro functional signaling assays, alanine-scanning mutagenesis of C-terminal peptides, KLB binding assays, in vivo obese mouse pharmacology","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis (Ala-scan), in vitro reconstitution assays, and in vivo validation in a single study","pmids":["29789271"],"is_preprint":false},{"year":2020,"finding":"FGF21 structure was determined by NMR spectroscopy; the non-canonical flexible β-trefoil conformation affects folding of the β2-β3 hairpin and overall protein stability. A chimeric FGF21-FGF19 variant (FGF21SS) with modulated folding dynamics showed better thermostability, improved insulin sensitivity, and reduced blood glucose in ob/ob mice without inducing hepatocyte proliferation.","method":"NMR spectroscopy, chimeric protein design, thermostability assays, in vitro adipocyte insulin signaling assay, ob/ob mouse blood glucose and insulin measurement","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural determination by NMR with functional validation via mutagenesis/chimera and in vivo testing, single lab","pmids":["33295692"],"is_preprint":false},{"year":2020,"finding":"Pancreatitis is associated with loss of FGF21 expression in exocrine pancreas due to ISR activation inducing ATF3, a transcriptional repressor that directly binds specific sites on the Fgf21 promoter. FGF21 replacement mitigates ISR and resolves pancreatitis in three mouse models; ATF3 binding sites are conserved in human FGF21 promoter.","method":"ISR activation in cultured acinar cells and mouse pancreata, ATF3 chromatin immunoprecipitation on Fgf21 promoter, three mouse pancreatitis models, recombinant FGF21 pharmacological rescue, PERK inhibitor experiments, human pancreatitis tissue analysis","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — promoter binding (ChIP), genetic and pharmacological models, human tissue validation, multiple mechanistic layers","pmids":["31915301"],"is_preprint":false},{"year":2023,"finding":"FGF21 counteracts ethanol-induced intoxication by stimulating arousal via direct activation of noradrenergic neurons in the locus coeruleus, without changing ethanol catabolism. FGF21-deficient mice take longer to recover from ethanol; pharmacological FGF21 accelerates recovery. FGF21 does not counteract sedation by ketamine, diazepam, or pentobarbital, indicating ethanol specificity.","method":"FGF21 global knockout mice, pharmacological FGF21 administration, righting reflex and ataxia assays, locus coeruleus neuronal recording/activation studies, multiple sedative agent controls","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, pharmacological rescue, specificity controls, neuronal mechanism identified, published in Cell Metabolism","pmids":["36889282"],"is_preprint":false},{"year":2022,"finding":"CNOT6L deadenylase controls FGF21 mRNA stability in hepatocytes. CNOT6L inhibition stabilizes Fgf21 mRNA, elevating serum FGF21 protein, which then acts on liver and adipose tissue to induce energy expenditure and lipid consumption. A small-molecule CNOT6L inhibitor that increases GDF15 and FGF21 improves diet-induced metabolic syndrome.","method":"CNOT6L inhibition (genetic and pharmacological), mRNA stability assays, serum hepatokine measurement, small-molecule screening, metabolic phenotyping in diet-induced obese mice","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — mRNA stability mechanism defined, genetic and pharmacological interventions, small-molecule validation in vivo","pmids":["35385705"],"is_preprint":false},{"year":2022,"finding":"FGF21 enhances adiponectin production, which in turn acts on cardiomyocytes (or FGF21 directly targets cardiomyocytes) to suppress PDK4 via PI3K/AKT signaling, thereby promoting mitochondrial bioenergetics and protecting against HFpEF. APN deletion abrogates FGF21's protective effects against HFpEF; genetic PDK4 inactivation mimics FGF21 protection.","method":"Global and adipose-specific FGF21 KO mice, HFD+L-NAME HFpEF model, FGF21 replenishment, adiponectin KO, PDK4 genetic inactivation, PI3K/AKT pathway assays, mitochondrial bioenergetics measurement","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (FGF21 KO, adipose-specific KO, APN KO, PDK4 KO), defined PI3K/AKT/PDK4 signaling axis","pmids":["39955281"],"is_preprint":false},{"year":2022,"finding":"Liver-derived FGF21 activates GABA-containing neurons expressing dopamine receptor 2 in the lateral hypothalamic area and zona incerta to mediate prolonged breastfeeding-induced protection against obesity, via enhanced BAT thermogenesis and energy expenditure. Tanycyte-controlled access to the hypothalamus gates FGF21 action.","method":"Delayed weaning rat model, transgenic mice, metabolic phenotyping, brain-specific pathway (tanycyte access), specific neuronal circuit identification (GABAergic DR2 neurons), hepatic FGF21 manipulation","journal":"Nature metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in-depth mechanistic dissection of neuronal circuit in multiple animal models, single published study","pmids":["35879461"],"is_preprint":false},{"year":2022,"finding":"Central FGF21, produced not in the hypothalamus but in the retrosplenial cortex (RSC), enhances spatial memory by prolonging long-term potentiation in the hippocampus and activating hippocampal neurons, without regulating peripheral energy homeostasis or sugar intake.","method":"FGF21-Cre lineage tracing mouse model, RSC-specific FGF21 expression mapping, hippocampal LTP electrophysiology, spatial memory behavioral assays, energy homeostasis and sugar preference assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic lineage tracing identifying brain source, LTP electrophysiology, behavioral and metabolic phenotyping with clear dissociation of central vs. peripheral effects","pmids":["36001982"],"is_preprint":false},{"year":2016,"finding":"PPARβ/δ deficiency in hepatocytes increases FGF21 expression via upregulation of the heme-regulated eIF2α kinase (HRI), which causes enhanced phospho-eIF2α and ATF4, driving Fgf21 transcription. siRNA knockdown confirmed HRI as a regulator of hepatic FGF21 expression, and pharmacological HRI activation increased FGF21 and reduced hepatic steatosis in an FGF21-dependent manner.","method":"PPARβ/δ knockout mice, siRNA knockdown of HRI and PPARβ/δ in primary hepatocytes, eIF2α and ATF4 western blotting, HRI pharmacological activator, Fgf21-null mice as controls","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — siRNA knockdown, genetic KO, pharmacological rescue, and FGF21-null validation in one study","pmids":["27486236"],"is_preprint":false},{"year":2016,"finding":"Lactate rapidly induces FGF21 expression and secretion in adipocytes via a p38-MAPK-dependent, NADH/NAD-independent pathway. Pyruvate and ketone bodies similarly activate FGF21, suggesting sensing of intermediate metabolites drives adipose FGF21 release.","method":"Lactate treatment of adipocytes, pharmacological p38-MAPK inhibition, knockout mouse models, NADH/NAD manipulation, FGF21 mRNA and secretion assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection and genetic models, single lab","pmids":["26769382"],"is_preprint":false},{"year":2012,"finding":"Metformin stimulates FGF21 expression in primary rat and human hepatocytes via AMPK activation; this effect is blocked by the AMPK inhibitor Compound C.","method":"Primary rat and human hepatocyte cultures, metformin treatment, AMPK inhibitor (Compound C), FGF21 mRNA and protein measurement","journal":"Experimental diabetes research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection in human primary cells, replicated in rat and human hepatocytes","pmids":["23118742"],"is_preprint":false},{"year":2016,"finding":"Leptin increases FGF21 expression in vivo in rats and in HepG2 hepatocytes, and this effect is mediated by STAT3 activation.","method":"Leptin injection in Wistar rats, HepG2 cell treatment, STAT3 inhibition/activation, FGF21 mRNA/protein measurement","journal":"Cellular physiology and biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell line (HepG2 hepatocarcinoma) and rat in vivo, limited mechanistic follow-up of STAT3 pathway","pmids":["26982498"],"is_preprint":false},{"year":2020,"finding":"In MDCK mechanical cell competition, scribble-knockdown (scribKD) cells secrete FGF21 via the ASK1-p38 pathway, which attracts surrounding wild-type cells and drives their mechanical elimination of scribKD cells through FGFR1 signaling in wild-type cells.","method":"FGF21 knockdown in scribKD MDCK cells, FGFR1 loss-of-function in WT cells, conditioned medium cell motility assays, ASK1-p38 pathway pharmacology","journal":"Current biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown of FGF21 and FGFR1 with mechanistic pathway dissection; novel cellular context (cell competition), single lab","pmids":["33357449"],"is_preprint":false},{"year":2013,"finding":"FGF21 enhances BMP-2-induced osteogenesis by upregulating BMP-2-dependent Smad signaling (not p44/42 MAPK). BMP-2 in turn decreases endogenous FGF21 mRNA expression, forming a negative feedback loop.","method":"C2C12 cell osteogenic differentiation assay, alkaline phosphatase activity, matrix mineralization, Smad and MAPK phosphorylation western blotting, FGF21 mRNA measurement","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single cell line model, single lab, no in vivo validation","pmids":["23416071"],"is_preprint":false},{"year":2020,"finding":"FGF21 impedes peripheral nervous system myelin development by activating the p38 MAPK/c-Jun signaling axis in Schwann cells (not ERK). Anti-FGF21 antibody accelerates peripheral myelination in neonatal rats.","method":"Primary Schwann cell culture, recombinant FGF21 treatment, p38 MAPK and ERK pharmacological inhibition, gene knockdown, neonatal rat FGF21 injection, anti-FGF21 antibody infusion, myelin gene expression analysis","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection plus in vivo injection and antibody blockade studies, single lab","pmids":["32657446"],"is_preprint":false},{"year":2020,"finding":"FGF21 protects chondrocytes from apoptosis, senescence, and ECM catabolism by enhancing autophagy flux via TFEB nuclear translocation through activation of the SIRT1-mTOR signaling pathway, and reduces OA in a DMM mouse model.","method":"TBHP-induced chondrocyte stress model, FGF21 treatment, autophagy flux assay, TFEB nuclear translocation imaging, SIRT1-mTOR pathway western blotting, autophagy inhibitor (CQ), DMM mouse OA model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined signaling pathway with pharmacological autophagy inhibition rescue, in vivo DMM model, single lab","pmids":["34556628"],"is_preprint":false},{"year":2022,"finding":"FGF21 alleviates acute liver injury by enhancing SIRT1-mediated autophagy. Mechanistically, exogenous FGF21 upregulates LC3-II and Beclin1 (autophagy markers) via SIRT1 upregulation; SIRT1 knockdown by lentiviral RNAi reverses FGF21's hepatoprotective effect.","method":"CCl4-induced ALI mouse model, L02 hepatocyte cell line, FGF21 treatment, SIRT1 lentiviral RNAi knockdown in mice and cells, autophagy markers (LC3-II, Beclin1), ALT/AST/cytokine assays","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown reversal experiment in vivo and in vitro, defined SIRT1-autophagy mechanism, single lab","pmids":["34984826"],"is_preprint":false},{"year":2024,"finding":"Excess BCAA decreases hepatic FGF21 production by inhibiting PPARα signaling; reduced FGF21 leads to higher cardiac LAT1 expression via transcription factor Zbtb7c, increasing cardiac BCAA uptake and mTOR-driven mitochondrial damage and apoptosis. Fecal microbiota transplant from healthy mice alleviated cardiac dysfunction in T1D mice, but this was abolished by FGF21 knockdown.","method":"T1D mouse model, gut microbiota BCAA profiling, FGF21 knockdown, PPARα signaling pathway assay, LAT1 and Zbtb7c expression, mTOR signaling, fecal microbiota transplant, cardiac function assays","journal":"Microbiome","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FGF21 knockdown essential for pathway definition, multi-organ mechanistic dissection, single lab","pmids":["39182099"],"is_preprint":false},{"year":2021,"finding":"FGF21 attenuates pulmonary arterial hypertension by suppressing miR-27b expression in HPAECs, which in turn de-represses PPARγ (a direct miR-27b target validated by luciferase assay), reducing NF-κB-driven inflammation and endothelial dysfunction.","method":"Hypoxia-induced HPAEC model, FGF21 treatment, miR-27b overexpression/inhibition, luciferase reporter assay for miR-27b/PPARγ targeting, NF-κB pathway assays, inflammatory cytokine measurement","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase validation of miR-27b/PPARγ targeting plus FGF21-mediated pathway, single lab, in vitro","pmids":["33907846"],"is_preprint":false},{"year":2020,"finding":"FGF21 inhibits retinal and choroidal neovascularization, and this protective effect requires adiponectin (APN). FGF21 administration inhibited TNF-α but not VEGFA expression in neovascular eyes; APN-deficient mice were not protected by FGF21.","method":"Mouse oxygen-induced retinopathy model, VLDLR-deficient retinal angiomatous proliferation model, laser-induced choroidal neovascularization model, FGF21 administration, FGF21-KO, APN-KO mice, TNF-α and VEGFA measurement","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — three independent neovascularization models, two genetic knockout models (FGF21-KO and APN-KO) identifying APN as essential mediator","pmids":["28199833"],"is_preprint":false},{"year":2020,"finding":"FGF21 attenuates neuroinflammation after subarachnoid hemorrhage by promoting AMPK-dependent mitophagy in microglia, preventing mitochondrial DNA release and thereby suppressing cGAS-STING pathway activation. Conditional STING knockout in microglia ameliorated SAH-induced inflammation.","method":"SAH mouse model, recombinant FGF21 treatment, AMPK pharmacological manipulation, mitophagy assay, mtDNA cytoplasmic release measurement, cGAS-STING pathway assays, microglial STING conditional knockout, RNA sequencing, behavioral assays","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined AMPK-mitophagy-cGAS-STING mechanistic cascade with genetic STING KO validation, single lab","pmids":["38720350"],"is_preprint":false},{"year":2021,"finding":"FGF21 has a direct pyrexic effect on body temperature that is independent of UCP1 and can occur without changes in energy expenditure. In UCP1-knockout mice, FGF21 increases body temperature by reducing heat loss (e.g., reduced tail surface temperature) rather than increasing heat production.","method":"UCP1-knockout mice, FGF21 administration at multiple ambient temperatures, indirect calorimetry, body temperature telemetry, tail surface temperature (infrared thermography), BAT temperature measurement","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic UCP1 KO with pharmacological FGF21, multiple temperature conditions, mechanistic dissection of pyrexia vs. hyperthermia","pmids":["34418595"],"is_preprint":false},{"year":2022,"finding":"FGF21 effects on hepatic lipid metabolism and adiponectin secretion are sex-dependent. FGF21 reduced liver triglycerides and stimulated adiponectin via the adrenergic receptor→cAMP→EPAC signaling pathway in obese male mice but inhibited this pathway in females. Ovariectomized and reproductively senescent old females did not respond to FGF21 for liver TG or adiponectin, indicating the sex dependence is not mediated by an active female reproductive system.","method":"Male and female obese mouse models, FGF21 treatment, adiponectin measurement, adrenergic receptor-cAMP-EPAC pathway assays, ovariectomy model, aged female mice, liver triglyceride quantification","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sex-stratified analysis with surgical reproductive manipulation, defined adrenergic-cAMP-EPAC mechanism, single lab","pmids":["35998055"],"is_preprint":false},{"year":2020,"finding":"PPARα-dependent DNA demethylation of the Fgf21 promoter in postnatal mouse liver regulates FGF21 gene expression. Targeted DNA demethylation using CRISPR/dCas9-TET1 at the Fgf21 promoter in PPARα-deficient mice restored fasting- and PPARα ligand-induced Fgf21 expression, providing direct evidence that DNA methylation status at the Fgf21 promoter determines the magnitude of gene expression response.","method":"CRISPR/dCas9-SunTag-scFv-TET1CD system, Fgf21 promoter-specific demethylation, Hepa1-6 cells, PPARα-deficient mice, bisulfite sequencing, PPARα agonist treatment, fasting experiment","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — CRISPR epigenome editing with site-specific targeting, direct causal test of DNA methylation on FGF21 expression in vitro and in vivo","pmids":["32198422"],"is_preprint":false},{"year":2022,"finding":"FGF21 reduces hypercholesterolaemia and atherosclerosis by promoting BAT activation and WAT browning, which enhances selective uptake of fatty acids from triglyceride-rich lipoproteins into thermogenic adipose tissues, accelerating clearance of cholesterol-enriched remnants by the liver.","method":"APOE*3-Leiden.CETP hypercholesterolaemic mouse model, pharmacological FGF21 administration, BAT activation measurement, WAT browning assessment, lipoprotein clearance assays, atherosclerotic lesion quantification, hepatic gene expression profiling","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined mechanistic pathway (BAT activation → TRL clearance → cholesterol reduction) with multiple metabolic readouts, single lab","pmids":["33693480"],"is_preprint":false},{"year":2019,"finding":"FGF21 and PPARγ mutually promote each other's expression in pulmonary artery smooth muscle cells via the AMPK/PGC-1α pathway and the FGF21 co-receptor KLB, attenuating hypoxia-induced pulmonary hypertension.","method":"Hypoxia-induced pulmonary hypertension mouse model, FGF21 and PPARγ expression assays, AMPK/PGC-1α pathway analysis, KLB protein assay, in vitro and in vivo experiments","journal":"Experimental biology and medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway assays without rigorous genetic dissection, single lab, limited mechanistic validation","pmids":["30714402"],"is_preprint":false},{"year":2023,"finding":"FGF21 inhibits FGF21 promoter via the FGFR-KLB-FGF21 autocrine axis to suppress CYP7A1 promoter activity in liver cells (hepatocyte autocrine mechanism). FGF21 protein directly inhibited CYP7A1 promoter activity in HepG2 cells, and this effect was mediated by conditioned medium from FGF21-overexpressing cells but not abolished by deletion of putative phosphorylated FGF21 effector response elements.","method":"HepG2 transfection with FGF21, luciferase reporter for CYP7A1 promoter, conditioned medium transfer, response element deletion mutants","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — luciferase reporter assay in hepatocarcinoma cell line, mechanism not fully resolved, single lab","pmids":["29883717"],"is_preprint":false},{"year":2019,"finding":"FGF21 mediates MSC senescence via AMPK signaling that regulates mitochondrial dynamics (fusion/fission balance). FGF21 depletion in MSCs enhanced mitochondrial fusion (via Mfn2) and mitochondrial ROS, driving senescence; AMPK activation or Mfn2 knockdown abrogated FGF21-depletion-induced senescence.","method":"FGF21 siRNA depletion in MSCs, Mfn2 siRNA knockdown, AMPK activator (AICAR), mitochondrial morphology (MitoTracker), ROS measurement (MitoSox), SA-β-gal staining","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two genetic knockdowns and pharmacological AMPK activation with defined mechanistic pathway, single lab","pmids":["31178962"],"is_preprint":false}],"current_model":"FGF21 is a stress- and nutrient-responsive hepatokine (also produced by BAT, skeletal muscle, exocrine pancreas, and other tissues) that signals through a heterodimeric receptor complex of FGF receptor 1c (and other FGFRs) with the obligate co-receptor β-Klotho; it acts on adipose tissue (driving browning, UCP1-dependent thermogenesis, and glucose uptake), the brain (hypothalamus, locus coeruleus, and retrosplenial cortex for macronutrient preference, arousal, and memory), liver, and other organs to regulate glucose homeostasis, lipid oxidation, and energy expenditure—largely through downstream mediators including adiponectin (itself activating AMPK and PI3K/AKT signaling) and central noradrenergic circuits—with its transcription controlled by PPARα, ATF2/ATF4 via the integrated stress response, MyoD in muscle, and CREBH (degraded by HRD1-ERAD ubiquitination), and its mRNA stability regulated by the CNOT6L deadenylase."},"narrative":{"mechanistic_narrative":"FGF21 is a stress- and nutrient-responsive endocrine factor secreted by multiple tissues—liver, brown adipose tissue, skeletal muscle, and exocrine pancreas—that signals through FGFR–β-Klotho (KLB) receptor complexes to coordinate systemic glucose homeostasis, lipid oxidation, thermoregulation, and central behavioral responses to diet [PMID:21317437, PMID:18948104, PMID:28089565, PMID:31167139, PMID:30679672]. Its C-terminal sequence is the primary determinant of KLB binding and receptor activation, and its non-canonical flexible β-trefoil fold governs stability—features exploited to engineer super-agonist and chimeric variants with improved metabolic efficacy [PMID:29789271, PMID:33295692]. In the periphery, FGF21 acts largely through adiponectin: it raises adipocyte adiponectin secretion to mediate insulin sensitization, cardioprotection (suppressing cardiomyocyte PDK4 via PI3K/AKT), and inhibition of retinal/choroidal neovascularization, with these effects lost in adiponectin-null mice [PMID:23663741, PMID:39955281, PMID:28199833]. FGF21 also drives glucose disposal through UCP1-dependent BAT thermogenesis, while a separate UCP1-independent pyrexic action raises body temperature by reducing heat loss [PMID:26586424, PMID:34418595]. In the brain, FGF21 signals through CNS β-Klotho to reduce sweet and alcohol preference, shift macronutrient preference during dietary protein restriction, and drive sympathetic outflow to BAT for thermoregulation; distinct circuits include locus coeruleus noradrenergic neurons (counteracting ethanol intoxication) and retrosplenial-cortex-derived FGF21 that enhances hippocampal LTP and spatial memory [PMID:26724861, PMID:31167139, PMID:30679672, PMID:36889282, PMID:36001982]. FGF21 transcription is controlled by multiple inputs—PPARα (including PPARα-dependent promoter DNA demethylation), MyoD and ROS→p38→ATF2 in muscle, β-adrenergic/cAMP/PKA/p38/ATF2 in BAT, HRI→eIF2α→ATF4 in hepatocytes, and the integrated stress response acting through ATF3 (a repressor) in pancreas—while the CREBH transcription factor is gated by HRD1-ERAD ubiquitination and Fgf21 mRNA stability is set by the CNOT6L deadenylase [PMID:21317437, PMID:30389664, PMID:25055037, PMID:31915301, PMID:35385705, PMID:27486236, PMID:32198422]. Dietary protein restriction extends lifespan and improves metabolic health in an FGF21-dependent manner [PMID:28811495, PMID:35393401].","teleology":[{"year":2008,"claim":"Established that skeletal muscle is an FGF21 source and that PI3K/Akt1 signaling drives its muscle expression, broadening FGF21 beyond a liver-only hepatokine.","evidence":"Akt1 muscle-specific transgenic mice plus PI3K inhibition in cultured myocytes","pmids":["18948104"],"confidence":"Medium","gaps":["Physiological stimulus driving muscle Akt1/FGF21 in vivo not defined","Systemic role of muscle-derived FGF21 not isolated from liver source"]},{"year":2011,"claim":"Identified BAT as a thermogenically activated FGF21 source and defined the β-adrenergic/cAMP/PKA/p38/ATF2 transcriptional pathway, linking sympathetic tone to FGF21 production.","evidence":"Arteriovenous difference across BAT, β-adrenergic pharmacology, p38 inhibition, ATF2 promoter binding, in vivo cold exposure","pmids":["21317437"],"confidence":"High","gaps":["Relative contribution of BAT vs liver FGF21 to circulating pool not resolved here"]},{"year":2013,"claim":"Defined adiponectin as an obligatory downstream effector of FGF21's systemic insulin-sensitizing action, separating it from direct adipose ERK signaling.","evidence":"Adiponectin-knockout mice with FGF21 administration and metabolic readouts","pmids":["23663741"],"confidence":"High","gaps":["Mechanism by which FGF21 induces adiponectin transcription not detailed","Adiponectin-independent FGF21 actions not enumerated"]},{"year":2014,"claim":"Showed MyoD is the major muscle transcriptional regulator of FGF21 and that mitochondrial dysfunction induces FGF21 via ROS→p38→ATF2, casting FGF21 as a mitochondrial-stress signal.","evidence":"OXPHOS inhibitors, MyoD knockdown, ROS measurement, p38 inhibition, ATF2 promoter binding in muscle cells","pmids":["25055037"],"confidence":"High","gaps":["In vivo confirmation of MyoD requirement not shown","Single-lab data"]},{"year":2015,"claim":"Demonstrated CNS β-Klotho-dependent FGF21 signaling reduces sweet and alcohol preference with reduced accumbal dopamine, establishing a central behavioral axis for FGF21.","evidence":"FGF21 administration in mice and monkeys, CNS-specific KLB knockout, accumbal dopamine measurement, preference assays","pmids":["26724861"],"confidence":"High","gaps":["Specific neuronal targets and circuit not mapped here","Link between dopamine change and preference is correlative"]},{"year":2015,"claim":"Separated FGF21's weight-lowering effect from its glucose-clearance effect, showing the latter requires UCP1-dependent BAT thermogenesis.","evidence":"Ucp1-knockout mice with FGF21 administration, glucose tolerance tests, BAT temperature","pmids":["26586424"],"confidence":"High","gaps":["How UCP1 thermogenesis mechanistically drives glucose disposal not detailed"]},{"year":2016,"claim":"Expanded transcriptional control of hepatic FGF21 to the HRI→eIF2α→ATF4 integrated-stress arm (de-repressed upon PPARβ/δ loss) and to AMPK (metformin), STAT3 (leptin), and metabolite sensing.","evidence":"PPARβ/δ KO mice and HRI siRNA with eIF2α/ATF4 readout; metformin/Compound C in hepatocytes; leptin/STAT3 in rats and HepG2; lactate/p38 in adipocytes","pmids":["27486236","23118742","26982498","26769382"],"confidence":"Medium","gaps":["Leptin/STAT3 link is Low-confidence single cell line","Integration of these inputs into a unified regulatory logic not established"]},{"year":2017,"claim":"Revealed an autocrine/paracrine FGF21 function in exocrine pancreas, stimulating digestive enzyme secretion via FGFR–β-Klotho and PLC-IP3R calcium signaling, with loss causing zymogen accumulation and ER stress.","evidence":"FGF21 and β-Klotho KO, acinar-specific KLB deletion, recombinant FGF21 rescue, calcium imaging, PLC-IP3R pharmacology","pmids":["28089565"],"confidence":"High","gaps":["Whether circulating vs locally produced FGF21 dominates acinar action not fully resolved"]},{"year":2017,"claim":"Established FGF21 as essential for the lifespan-extending and metabolic benefits of dietary protein restriction, linking the hormone to healthy aging.","evidence":"FGF21 global knockout, long-term protein restriction, lifespan and frailty assessment","pmids":["28811495","35393401"],"confidence":"High","gaps":["Tissue source and target circuit mediating longevity effect not isolated here"]},{"year":2018,"claim":"Defined upstream control of FGF21 production by HRD1-ERAD ubiquitination of the ER-tethered transcription factor CREBH at K294, coupling nutrient state (refeeding) to FGF21 suppression.","evidence":"Liver-specific HRD1 KO, in vitro ubiquitination with K294 mutagenesis, proteasome inhibition, refeeding","pmids":["30389664"],"confidence":"High","gaps":["Signal triggering CREBH activation versus degradation balance not fully mapped"]},{"year":2018,"claim":"Mapped the C-terminal sequence as the primary KLB-binding/receptor-activation determinant, enabling antagonist peptides and engineered super-agonists.","evidence":"In vitro signaling assays, alanine-scanning mutagenesis, KLB binding assays, obese mouse pharmacology","pmids":["29789271"],"confidence":"High","gaps":["Structural basis of the C-terminus–KLB contact not solved here"]},{"year":2019,"claim":"Showed brain KLB signaling, not direct adipose action, mediates the adaptive response to protein restriction (macronutrient preference, energy expenditure, glucose), centralizing FGF21's site of action.","evidence":"Brain-specific KLB KO and whole-body FGF21 KO with protein restriction phenotyping","pmids":["31167139"],"confidence":"High","gaps":["Specific brain neuronal population not identified in this study"]},{"year":2019,"claim":"Demonstrated liver, not adipose, is the cold-induced circulating FGF21 source, and central KLB signaling drives sympathetic BAT activation while adipose-direct FGF21 signaling is dispensable for thermoregulation.","evidence":"Liver-, adipose-, and adipose-KLB-specific KO mice, CNS FGF21 blockade, cold exposure, temperature monitoring","pmids":["30679672"],"confidence":"High","gaps":["Identity of CNS thermoregulatory FGF21-target neurons not defined here"]},{"year":2020,"claim":"Solved the FGF21 NMR structure, attributing its instability to a non-canonical flexible β-trefoil and engineering a folding-stabilized chimera with better glycemic efficacy and no mitogenic effect.","evidence":"NMR spectroscopy, chimera design, thermostability assays, ob/ob mouse glucose/insulin","pmids":["33295692"],"confidence":"High","gaps":["Receptor-bound structure not determined","Single lab"]},{"year":2020,"claim":"Added PPARα-dependent Fgf21 promoter DNA demethylation as a determinant of FGF21 expression magnitude, demonstrated causally by targeted dCas9-TET1 demethylation.","evidence":"CRISPR/dCas9-TET1 epigenome editing at the Fgf21 promoter in PPARα-deficient mice and Hepa1-6 cells, bisulfite sequencing","pmids":["32198422"],"confidence":"High","gaps":["Developmental timing and enzymes setting methylation not fully defined"]},{"year":2020,"claim":"Identified ATF3 as an integrated-stress-response repressor that directly silences the Fgf21 promoter in pancreatitis, with FGF21 replacement resolving disease and conserved human ATF3 sites.","evidence":"ATF3 ChIP on Fgf21 promoter, three pancreatitis mouse models, recombinant FGF21 rescue, PERK inhibition, human tissue","pmids":["31915301"],"confidence":"High","gaps":["Whether ATF3 repression operates in other FGF21-producing tissues not tested"]},{"year":2021,"claim":"Dissociated FGF21's pyrexic action from thermogenesis, showing a UCP1-independent rise in body temperature achieved by reducing heat loss.","evidence":"UCP1-KO mice, FGF21 across ambient temperatures, calorimetry, telemetry, tail thermography","pmids":["34418595"],"confidence":"High","gaps":["Effector mechanism for reduced heat loss (e.g. vasomotor control) not specified"]},{"year":2022,"claim":"Defined CNOT6L deadenylase as a post-transcriptional brake on Fgf21 mRNA stability, providing a druggable node to raise circulating FGF21.","evidence":"Genetic and pharmacological CNOT6L inhibition, mRNA stability assays, small-molecule validation in diet-induced obese mice","pmids":["35385705"],"confidence":"High","gaps":["Specificity of CNOT6L for Fgf21 versus other transcripts not bounded"]},{"year":2022,"claim":"Resolved central FGF21 circuit diversity: liver-derived FGF21 acts on hypothalamic GABAergic DR2 neurons (gated by tanycytes) for breastfeeding-induced obesity protection, while RSC-derived FGF21 enhances hippocampal LTP and spatial memory independent of energy homeostasis.","evidence":"FGF21-Cre lineage tracing, RSC mapping, hippocampal LTP electrophysiology, delayed-weaning models, behavioral and metabolic assays","pmids":["35879461","36001982"],"confidence":"High","gaps":["RSC-derived FGF21 source mechanism is Medium-confidence single study for the hypothalamic circuit","How distinct FGF21 sources access separate circuits not unified"]},{"year":2022,"claim":"Extended the FGF21–adiponectin axis to cardioprotection, showing it suppresses cardiomyocyte PDK4 via PI3K/AKT to preserve mitochondrial bioenergetics in HFpEF, and revealed sex-dependent adrenergic-cAMP-EPAC control of adiponectin/hepatic lipid responses.","evidence":"FGF21, adipose-specific FGF21, adiponectin and PDK4 KO mice in HFpEF; sex-stratified obese models with ovariectomy and adrenergic-cAMP-EPAC assays","pmids":["39955281","35998055"],"confidence":"Medium","gaps":["Whether cardiac protection is via circulating adiponectin or direct cardiomyocyte FGF21 not fully separated","Molecular basis of sex divergence in EPAC signaling unresolved"]},{"year":2023,"claim":"Identified locus coeruleus noradrenergic neurons as the substrate by which FGF21 counteracts ethanol intoxication through arousal, with specificity for ethanol over other sedatives.","evidence":"FGF21 KO and pharmacological rescue, righting/ataxia assays, LC neuronal activation, sedative-agent controls","pmids":["36889282"],"confidence":"High","gaps":["Receptor and intracellular pathway in LC neurons not detailed"]},{"year":null,"claim":"How the diverse upstream transcriptional, epigenetic, and post-transcriptional inputs and the multiple tissue sources are integrated to set context-specific FGF21 output, and how distinct central circuits are selectively engaged, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking source tissue to specific peripheral/central target","Receptor-level structural basis of KLB engagement in each tissue not solved","Many disease-context mechanisms (atherosclerosis, OA, neuroinflammation, PAH) rest on single-lab studies"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[4,11,0]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,5,7]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,2,7]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,9,16,35]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,7,4]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,8,13,19,34]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[15]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[14,18,17]}],"complexes":[],"partners":["KLB","FGFR1","ADIPOQ"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NSA1","full_name":"Fibroblast growth factor 21","aliases":[],"length_aa":209,"mass_kda":22.3,"function":"Stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression (but not SLC2A4/GLUT4 expression). Activity requires the presence of KLB. Regulates systemic glucose homeostasis and insulin sensitivity","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9NSA1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGF21","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGF21","total_profiled":1310},"omim":[{"mim_id":"621481","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 14A (ENCEPHALOMYOPATHIC TYPE); MTDPS14A","url":"https://www.omim.org/entry/621481"},{"mim_id":"620879","title":"FIBROBLAST GROWTH FACTOR-BINDING PROTEIN 3; FGFBP3","url":"https://www.omim.org/entry/620879"},{"mim_id":"615812","title":"ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3","url":"https://www.omim.org/entry/615812"},{"mim_id":"612122","title":"PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 7; PNPLA7","url":"https://www.omim.org/entry/612122"},{"mim_id":"611998","title":"cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 3; CREB3L3","url":"https://www.omim.org/entry/611998"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"liver","ntpm":79.4}],"url":"https://www.proteinatlas.org/search/FGF21"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9NSA1","domains":[{"cath_id":"2.80.10.50","chopping":"50-150_157-163","consensus_level":"high","plddt":90.4774,"start":50,"end":163}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NSA1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NSA1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NSA1-F1-predicted_aligned_error_v6.png","plddt_mean":76.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGF21","jax_strain_url":"https://www.jax.org/strain/search?query=FGF21"},"sequence":{"accession":"Q9NSA1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NSA1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NSA1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NSA1"}},"corpus_meta":[{"pmid":"23663741","id":"PMC_23663741","title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.","date":"2013","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23663741","citation_count":585,"is_preprint":false},{"pmid":"21317437","id":"PMC_21317437","title":"Thermogenic activation induces FGF21 expression and release in brown adipose tissue.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21317437","citation_count":516,"is_preprint":false},{"pmid":"32764725","id":"PMC_32764725","title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.","date":"2020","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32764725","citation_count":485,"is_preprint":false},{"pmid":"18948104","id":"PMC_18948104","title":"FGF21 is an Akt-regulated myokine.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18948104","citation_count":357,"is_preprint":false},{"pmid":"26724861","id":"PMC_26724861","title":"FGF21 Regulates Sweet and Alcohol Preference.","date":"2015","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26724861","citation_count":284,"is_preprint":false},{"pmid":"31057418","id":"PMC_31057418","title":"FGF21 as Modulator of Metabolism in Health and Disease.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31057418","citation_count":258,"is_preprint":false},{"pmid":"25476453","id":"PMC_25476453","title":"Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.","date":"2014","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/25476453","citation_count":252,"is_preprint":false},{"pmid":"23667629","id":"PMC_23667629","title":"Acute exercise induces FGF21 expression in mice and in healthy humans.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23667629","citation_count":236,"is_preprint":false},{"pmid":"29987000","id":"PMC_29987000","title":"FGF21 gene therapy as treatment for obesity and insulin resistance.","date":"2018","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29987000","citation_count":231,"is_preprint":false},{"pmid":"31167139","id":"PMC_31167139","title":"FGF21 Signals Protein Status to the Brain and Adaptively Regulates Food Choice and Metabolism.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31167139","citation_count":191,"is_preprint":false},{"pmid":"33381084","id":"PMC_33381084","title":"FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33381084","citation_count":168,"is_preprint":false},{"pmid":"24749049","id":"PMC_24749049","title":"Inventing new medicines: The FGF21 story.","date":"2013","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24749049","citation_count":168,"is_preprint":false},{"pmid":"25071723","id":"PMC_25071723","title":"FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases.","date":"2014","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25071723","citation_count":166,"is_preprint":false},{"pmid":"23372041","id":"PMC_23372041","title":"Novel locus including FGF21 is associated with dietary macronutrient intake.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23372041","citation_count":159,"is_preprint":false},{"pmid":"24709036","id":"PMC_24709036","title":"FGF21-based pharmacotherapy--potential utility for metabolic disorders.","date":"2014","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/24709036","citation_count":146,"is_preprint":false},{"pmid":"31248786","id":"PMC_31248786","title":"Going Back to the Biology of FGF21: New Insights.","date":"2019","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/31248786","citation_count":132,"is_preprint":false},{"pmid":"25215270","id":"PMC_25215270","title":"FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases.","date":"2014","source":"Diabetes & metabolism journal","url":"https://pubmed.ncbi.nlm.nih.gov/25215270","citation_count":126,"is_preprint":false},{"pmid":"28089565","id":"PMC_28089565","title":"FGF21 Is an Exocrine Pancreas Secretagogue.","date":"2017","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28089565","citation_count":112,"is_preprint":false},{"pmid":"28552719","id":"PMC_28552719","title":"Regulation of longevity by FGF21: Interaction between energy metabolism and stress responses.","date":"2017","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28552719","citation_count":99,"is_preprint":false},{"pmid":"35393401","id":"PMC_35393401","title":"FGF21 is required for protein restriction to extend lifespan and improve metabolic health in male mice.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35393401","citation_count":99,"is_preprint":false},{"pmid":"26490383","id":"PMC_26490383","title":"FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties.","date":"2015","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/26490383","citation_count":98,"is_preprint":false},{"pmid":"26379627","id":"PMC_26379627","title":"FGF21 and Cardiac Physiopathology.","date":"2015","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26379627","citation_count":97,"is_preprint":false},{"pmid":"27678528","id":"PMC_27678528","title":"FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process.","date":"2016","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/27678528","citation_count":97,"is_preprint":false},{"pmid":"28525362","id":"PMC_28525362","title":"FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases.","date":"2017","source":"Hormone molecular biology and clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28525362","citation_count":95,"is_preprint":false},{"pmid":"34556628","id":"PMC_34556628","title":"Fibroblast growth factor 21 (FGF21) alleviates senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the SIRT1-mTOR signaling pathway.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34556628","citation_count":95,"is_preprint":false},{"pmid":"36594101","id":"PMC_36594101","title":"Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36594101","citation_count":91,"is_preprint":false},{"pmid":"32768941","id":"PMC_32768941","title":"FGF21 attenuates neurodegeneration through modulating neuroinflammation and oxidant-stress.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32768941","citation_count":90,"is_preprint":false},{"pmid":"28811495","id":"PMC_28811495","title":"Low protein-induced increases in FGF21 drive UCP1-dependent metabolic but not thermoregulatory endpoints.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28811495","citation_count":90,"is_preprint":false},{"pmid":"31178962","id":"PMC_31178962","title":"FGF21 Mediates Mesenchymal Stem Cell Senescence via Regulation of Mitochondrial Dynamics.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31178962","citation_count":85,"is_preprint":false},{"pmid":"32047920","id":"PMC_32047920","title":"FGF21 and the Physiological Regulation of Macronutrient Preference.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32047920","citation_count":79,"is_preprint":false},{"pmid":"33414764","id":"PMC_33414764","title":"FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33414764","citation_count":78,"is_preprint":false},{"pmid":"33264641","id":"PMC_33264641","title":"FGF21 in obesity and cancer: New insights.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33264641","citation_count":77,"is_preprint":false},{"pmid":"28844867","id":"PMC_28844867","title":"Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28844867","citation_count":77,"is_preprint":false},{"pmid":"32688339","id":"PMC_32688339","title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation.","date":"2020","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/32688339","citation_count":77,"is_preprint":false},{"pmid":"30679672","id":"PMC_30679672","title":"Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30679672","citation_count":74,"is_preprint":false},{"pmid":"33383173","id":"PMC_33383173","title":"FGF19 and FGF21: In NASH we trust.","date":"2020","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33383173","citation_count":66,"is_preprint":false},{"pmid":"32929325","id":"PMC_32929325","title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32929325","citation_count":65,"is_preprint":false},{"pmid":"28199833","id":"PMC_28199833","title":"FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28199833","citation_count":63,"is_preprint":false},{"pmid":"29890191","id":"PMC_29890191","title":"Homeostatic sensing of dietary protein restriction: A case for FGF21.","date":"2018","source":"Frontiers in neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29890191","citation_count":61,"is_preprint":false},{"pmid":"25055037","id":"PMC_25055037","title":"FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling.","date":"2014","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25055037","citation_count":61,"is_preprint":false},{"pmid":"26586424","id":"PMC_26586424","title":"FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26586424","citation_count":61,"is_preprint":false},{"pmid":"33693480","id":"PMC_33693480","title":"Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/33693480","citation_count":60,"is_preprint":false},{"pmid":"31108554","id":"PMC_31108554","title":"Circulating FGF21 Levels in Human Health and Metabolic Disease.","date":"2019","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/31108554","citation_count":59,"is_preprint":false},{"pmid":"30389664","id":"PMC_30389664","title":"HRD1-ERAD controls production of the hepatokine FGF21 through CREBH polyubiquitination.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30389664","citation_count":59,"is_preprint":false},{"pmid":"30257977","id":"PMC_30257977","title":"FGF21 Is a Hormonal Mediator of the Human \"Thrifty\" Metabolic Phenotype.","date":"2018","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30257977","citation_count":59,"is_preprint":false},{"pmid":"27125737","id":"PMC_27125737","title":"The FGF21 Receptor Signaling Complex: Klothoβ, FGFR1c, and Other Regulatory Interactions.","date":"2016","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/27125737","citation_count":58,"is_preprint":false},{"pmid":"23118742","id":"PMC_23118742","title":"Metformin stimulates FGF21 expression in primary hepatocytes.","date":"2012","source":"Experimental diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/23118742","citation_count":57,"is_preprint":false},{"pmid":"22587513","id":"PMC_22587513","title":"FGF21: The center of a transcriptional nexus in metabolic regulation.","date":"2012","source":"Current diabetes reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22587513","citation_count":57,"is_preprint":false},{"pmid":"35879461","id":"PMC_35879461","title":"Prolonged breastfeeding protects from obesity by hypothalamic action of hepatic FGF21.","date":"2022","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35879461","citation_count":56,"is_preprint":false},{"pmid":"36648330","id":"PMC_36648330","title":"FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/36648330","citation_count":55,"is_preprint":false},{"pmid":"36618930","id":"PMC_36618930","title":"The potential function and clinical application of FGF21 in metabolic diseases.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36618930","citation_count":55,"is_preprint":false},{"pmid":"26769382","id":"PMC_26769382","title":"Lactate induces FGF21 expression in adipocytes through a p38-MAPK pathway.","date":"2016","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26769382","citation_count":49,"is_preprint":false},{"pmid":"37260446","id":"PMC_37260446","title":"Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37260446","citation_count":44,"is_preprint":false},{"pmid":"33571698","id":"PMC_33571698","title":"Association between serum FGF21 level and sarcopenia in older adults.","date":"2021","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/33571698","citation_count":44,"is_preprint":false},{"pmid":"35385705","id":"PMC_35385705","title":"Deadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure.","date":"2022","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35385705","citation_count":43,"is_preprint":false},{"pmid":"36889282","id":"PMC_36889282","title":"FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system.","date":"2023","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36889282","citation_count":42,"is_preprint":false},{"pmid":"35620160","id":"PMC_35620160","title":"Hepatic hormone FGF21 and its analogues in clinical trials.","date":"2022","source":"Chronic diseases and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35620160","citation_count":42,"is_preprint":false},{"pmid":"31207147","id":"PMC_31207147","title":"Dietary Methionine Restriction Reduces Inflammation Independent of FGF21 Action.","date":"2019","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/31207147","citation_count":40,"is_preprint":false},{"pmid":"29883717","id":"PMC_29883717","title":"Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29883717","citation_count":39,"is_preprint":false},{"pmid":"29789271","id":"PMC_29789271","title":"Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.","date":"2018","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29789271","citation_count":39,"is_preprint":false},{"pmid":"26441837","id":"PMC_26441837","title":"Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD.","date":"2015","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26441837","citation_count":38,"is_preprint":false},{"pmid":"31915301","id":"PMC_31915301","title":"Pancreatitis is an FGF21-deficient state that is corrected by replacement therapy.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31915301","citation_count":38,"is_preprint":false},{"pmid":"34984826","id":"PMC_34984826","title":"FGF21 alleviates acute liver injury by inducing the SIRT1-autophagy signalling pathway.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34984826","citation_count":38,"is_preprint":false},{"pmid":"39182099","id":"PMC_39182099","title":"BCAA mediated microbiota-liver-heart crosstalk regulates diabetic cardiomyopathy via FGF21.","date":"2024","source":"Microbiome","url":"https://pubmed.ncbi.nlm.nih.gov/39182099","citation_count":37,"is_preprint":false},{"pmid":"27486236","id":"PMC_27486236","title":"Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency.","date":"2016","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/27486236","citation_count":36,"is_preprint":false},{"pmid":"36001982","id":"PMC_36001982","title":"Central FGF21 production regulates memory but not peripheral metabolism.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36001982","citation_count":35,"is_preprint":false},{"pmid":"21696361","id":"PMC_21696361","title":"FGF10 and FGF21 as regulators in adipocyte development and metabolism.","date":"2011","source":"Endocrine, metabolic & immune disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/21696361","citation_count":32,"is_preprint":false},{"pmid":"36006939","id":"PMC_36006939","title":"Aerobic exercise regulates FGF21 and NLRP3 inflammasome-mediated pyroptosis and inhibits atherosclerosis in mice.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36006939","citation_count":32,"is_preprint":false},{"pmid":"38720350","id":"PMC_38720350","title":"FGF21 attenuates neuroinflammation following subarachnoid hemorrhage through promoting mitophagy and inhibiting the cGAS-STING pathway.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38720350","citation_count":28,"is_preprint":false},{"pmid":"32198422","id":"PMC_32198422","title":"Targeted DNA demethylation of the Fgf21 promoter by CRISPR/dCas9-mediated epigenome editing.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32198422","citation_count":28,"is_preprint":false},{"pmid":"26982498","id":"PMC_26982498","title":"Leptin as a Potential Regulator of FGF21.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26982498","citation_count":28,"is_preprint":false},{"pmid":"38060447","id":"PMC_38060447","title":"Toward reconciling the roles of FGF21 in protein appetite, sweet preference, and energy expenditure.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38060447","citation_count":27,"is_preprint":false},{"pmid":"35983184","id":"PMC_35983184","title":"Multi-organ FGF21-FGFR1 signaling in metabolic health and disease.","date":"2022","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35983184","citation_count":27,"is_preprint":false},{"pmid":"20717167","id":"PMC_20717167","title":"FGF21 signalling pathway and metabolic traits - genetic association analysis.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20717167","citation_count":27,"is_preprint":false},{"pmid":"39955281","id":"PMC_39955281","title":"FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39955281","citation_count":26,"is_preprint":false},{"pmid":"22396172","id":"PMC_22396172","title":"FGF21 as a therapeutic reagent.","date":"2012","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/22396172","citation_count":26,"is_preprint":false},{"pmid":"23416071","id":"PMC_23416071","title":"Interactions between FGF21 and BMP-2 in osteogenesis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23416071","citation_count":26,"is_preprint":false},{"pmid":"27883936","id":"PMC_27883936","title":"Relationship between FGF21 and UCP1 levels under time-restricted feeding and high-fat diet.","date":"2016","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27883936","citation_count":24,"is_preprint":false},{"pmid":"35998055","id":"PMC_35998055","title":"FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35998055","citation_count":24,"is_preprint":false},{"pmid":"33907846","id":"PMC_33907846","title":"FGF21 attenuates hypoxia‑induced dysfunction and inflammation in HPAECs via the microRNA‑27b‑mediated PPARγ pathway.","date":"2021","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33907846","citation_count":23,"is_preprint":false},{"pmid":"30714402","id":"PMC_30714402","title":"Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.","date":"2019","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/30714402","citation_count":23,"is_preprint":false},{"pmid":"29332568","id":"PMC_29332568","title":"FGF-21 as a Potential Biomarker for Mitochondrial Diseases.","date":"2018","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29332568","citation_count":23,"is_preprint":false},{"pmid":"33295692","id":"PMC_33295692","title":"Dynamic folding modulation generates FGF21 variant against diabetes.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33295692","citation_count":22,"is_preprint":false},{"pmid":"34536190","id":"PMC_34536190","title":"FGF21 ameliorates hepatic fibrosis by multiple mechanisms.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34536190","citation_count":22,"is_preprint":false},{"pmid":"33357449","id":"PMC_33357449","title":"FGF21 Induced by the ASK1-p38 Pathway Promotes Mechanical Cell Competition by Attracting Cells.","date":"2020","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/33357449","citation_count":21,"is_preprint":false},{"pmid":"32332781","id":"PMC_32332781","title":"FGF21 Mimics a Fasting-Induced Metabolic State and Increases Appetite in Zebrafish.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32332781","citation_count":21,"is_preprint":false},{"pmid":"33554901","id":"PMC_33554901","title":"Neuroprotective Effects of the FGF21 Analogue LY2405319.","date":"2021","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/33554901","citation_count":21,"is_preprint":false},{"pmid":"32648929","id":"PMC_32648929","title":"The autocrine role of FGF21 in cultured adipocytes.","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32648929","citation_count":20,"is_preprint":false},{"pmid":"34295169","id":"PMC_34295169","title":"Advances in Biological Functions and Clinical Studies of FGF21.","date":"2021","source":"Diabetes, metabolic syndrome and obesity : targets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34295169","citation_count":19,"is_preprint":false},{"pmid":"33045954","id":"PMC_33045954","title":"Moderate-Intensity Continuous Training Improves FGF21 and KLB Expression in Obese Mice.","date":"2020","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/33045954","citation_count":19,"is_preprint":false},{"pmid":"34418595","id":"PMC_34418595","title":"A pyrexic effect of FGF21 independent of energy expenditure and UCP1.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34418595","citation_count":19,"is_preprint":false},{"pmid":"37462619","id":"PMC_37462619","title":"CRISPRa-based activation of Fgf21 and Fndc5 ameliorates obesity by promoting adipocytes browning.","date":"2023","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37462619","citation_count":18,"is_preprint":false},{"pmid":"35437883","id":"PMC_35437883","title":"FGF21 alleviates pulmonary hypertension by inhibiting mTORC1/EIF4EBP1 pathway via H19.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35437883","citation_count":18,"is_preprint":false},{"pmid":"34917032","id":"PMC_34917032","title":"Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine.","date":"2021","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34917032","citation_count":18,"is_preprint":false},{"pmid":"32657446","id":"PMC_32657446","title":"FGF21 impedes peripheral myelin development by stimulating p38 MAPK/c-Jun axis.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32657446","citation_count":18,"is_preprint":false},{"pmid":"34989130","id":"PMC_34989130","title":"FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34989130","citation_count":18,"is_preprint":false},{"pmid":"26052146","id":"PMC_26052146","title":"Selective Regulation of FGF19 and FGF21 Expression by Cellular and Nutritional Stress.","date":"2015","source":"Journal of nutritional science and vitaminology","url":"https://pubmed.ncbi.nlm.nih.gov/26052146","citation_count":18,"is_preprint":false},{"pmid":"24587261","id":"PMC_24587261","title":"Molecular characterization and mapping of Fgf21 gene in a foodfish species asian seabass.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24587261","citation_count":17,"is_preprint":false},{"pmid":"39383602","id":"PMC_39383602","title":"Methionine restriction alleviates diabetes-associated cognitive impairment via activation of FGF21.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/39383602","citation_count":16,"is_preprint":false},{"pmid":"26934832","id":"PMC_26934832","title":"Expression and purification of FGF21 in Pichia pastoris and its effect on fibroblast-cell migration.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26934832","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45252,"output_tokens":10113,"usd":0.143726,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20827,"output_tokens":6252,"usd":0.130218,"stage2_stop_reason":"end_turn"},"total_usd":0.273944,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"Adiponectin is a downstream effector of FGF21 in mediating its systemic insulin-sensitizing effects. FGF21 treatment enhanced adiponectin expression and secretion in adipocytes, raising serum adiponectin. Adiponectin knockout mice were refractory to FGF21-mediated alleviation of hyperglycemia, hypertriglyceridemia, insulin resistance, and hepatic steatosis, while FGF21-mediated ERK1/2 activation in adipose tissue remained intact.\",\n      \"method\": \"Adiponectin knockout mouse model, FGF21 administration, serum/tissue metabolic assays, Western blotting for insulin signaling\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal metabolic readouts, clearly dissects FGF21-adiponectin axis from direct ERK signaling\",\n      \"pmids\": [\"23663741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Brown adipose tissue (BAT) is a source of circulating FGF21 upon thermogenic activation. Norepinephrine acts via β-adrenergic/cAMP/PKA/p38 MAPK signaling to induce FGF21 gene transcription, with ATF2 binding the FGF21 promoter as the mediating transcription factor. Cold exposure in rats caused direct FGF21 release from BAT measured by arteriovenous differences.\",\n      \"method\": \"Arteriovenous difference measurements across interscapular BAT, blood flow measurement, β-adrenergic pharmacology, p38 MAPK inhibitors, ATF2 chromatin binding assays, in vivo cold exposure\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including direct in vivo AV-difference, pharmacological pathway dissection, and promoter binding\",\n      \"pmids\": [\"21317437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Skeletal muscle is a source of FGF21, and FGF21 expression and secretion in muscle are regulated by the PI3K/Akt1 signaling pathway. Akt1 transgenic mice showed elevated muscle and serum FGF21; insulin and LY294002 regulated FGF21 in cultured muscle cells.\",\n      \"method\": \"Akt1 skeletal muscle-specific transgenic mice, PI3K inhibitor (LY294002), cultured myocytes, serum FGF21 measurement, protein/mRNA expression\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic model plus pharmacological inhibition, single lab\",\n      \"pmids\": [\"18948104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FGF21 reduces sweet preference and alcohol preference via its co-receptor β-Klotho in the central nervous system, and correlates with reduced dopamine concentrations in the nucleus accumbens.\",\n      \"method\": \"FGF21 administration in mice and cynomolgus monkeys, CNS-specific β-Klotho knockout mice, dopamine measurement in nucleus accumbens, preference behavioral assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CNS-specific genetic knockout plus pharmacological intervention across two species with neurochemical readout\",\n      \"pmids\": [\"26724861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF21 acts as a secretagogue in pancreatic acinar cells, stimulating digestive enzyme secretion through an autocrine/paracrine mechanism requiring FGFR–β-Klotho signaling. FGF21 triggers intracellular calcium release via PLC-IP3R signaling. FGF21-deficient mice accumulate zymogen granules and show pancreatic ER stress; acinar-specific β-Klotho deletion also causes granule accumulation and prevents FGF21-stimulated secretion.\",\n      \"method\": \"FGF21 and β-Klotho knockout mice, acinar cell-specific β-Klotho deletion, recombinant FGF21 rescue, calcium imaging, PLC-IP3R pathway pharmacology, zymogen granule quantification\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reconstitution with recombinant FGF21, multiple genetic models, defined signaling mechanism via PLC-IP3R\",\n      \"pmids\": [\"28089565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF21 signaling in the brain via β-Klotho (KLB) is required for the adaptive physiological response to dietary protein restriction, including shifts in macronutrient preference toward protein, increased energy expenditure, and glucose homeostasis. Brain-specific KLB deletion or whole-body FGF21 deletion abolishes these responses.\",\n      \"method\": \"Brain-specific KLB knockout mice, whole-body FGF21 knockout mice, dietary protein restriction protocols, metabolic phenotyping, food preference assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent genetic models (brain-specific KLB KO and FGF21 global KO) with multiple orthogonal metabolic readouts\",\n      \"pmids\": [\"31167139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HRD1-ERAD E3 ubiquitin ligase controls FGF21 production by catalyzing polyubiquitin conjugation onto the ER-tethered transcription factor CREBH at lysine 294, targeting it for proteasomal degradation. Liver-specific HRD1 deletion prevents FGF21 suppression during refeeding, phenocopying FGF21 gain-of-function mice.\",\n      \"method\": \"Liver-specific HRD1 knockout mice, polyubiquitination assay, site-specific mutagenesis (K294), proteasome inhibition, refeeding experiments, serum FGF21 measurement\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro ubiquitination assay with mutagenesis, genetic KO model, and mechanistic pathway identification\",\n      \"pmids\": [\"30389664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Liver-derived FGF21 (not adipose-derived) enters circulation during acute cold exposure and is critical for thermoregulation. Central FGF21 signaling (via CNS β-Klotho) is necessary for maximal sympathetic drive to BAT to maintain thermoregulation; direct FGF21 signaling to adipose tissue is dispensable.\",\n      \"method\": \"Liver-specific FGF21 KO mice, adipose-specific FGF21 KO mice, adipose-specific KLB KO mice, pharmacological CNS FGF21 blockade, cold exposure studies, body temperature monitoring\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple tissue-specific genetic models dissecting tissue source and site of action, replicated across approaches\",\n      \"pmids\": [\"30679672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGF21 expression and secretion in muscle cells is controlled by MyoD as a major transcriptional regulator, and is induced by mitochondrial dysfunction via increased ROS → p38 MAPK → ATF2 binding to the proximal FGF21 promoter. MyoD is required for mitochondrial dysfunction-induced FGF21 expression in myogenic cells.\",\n      \"method\": \"Respiratory chain/OXPHOS inhibitors in cultured muscle cells, MyoD knockdown, ROS measurement, p38 MAPK inhibition, ATF2 promoter binding assay, FGF21 mRNA/protein/secretion assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — promoter binding assay, pharmacological pathway dissection, transcription factor knockdown, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"25055037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FGF21-mediated improvements in glucose clearance require UCP1. While FGF21 can lower body weight in both wild-type and Ucp1-knockout mice, rapid clearance of a glucose challenge by FGF21 is defective in Ucp1-KO mice, implicating UCP1-dependent thermogenesis in BAT as a mechanism for FGF21-driven glucose disposal.\",\n      \"method\": \"Ucp1 knockout mice, FGF21 administration, glucose tolerance tests, BAT temperature measurement, UCP1 protein quantification\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with pharmacological FGF21 treatment, clear dissection of weight-loss vs glucose-clearance effects\",\n      \"pmids\": [\"26586424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Dietary protein restriction increases lifespan, reduces frailty, and improves metabolic health in mice in an FGF21-dependent manner. FGF21-knockout mice fail to exhibit these metabolic responses to protein restriction and show accelerated aging phenotypes.\",\n      \"method\": \"FGF21 global knockout mice, long-term dietary protein restriction, lifespan measurement, frailty assessment, metabolic phenotyping\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with lifespan and multiple metabolic readouts, replicated in a subsequent Nature Communications paper (35393401)\",\n      \"pmids\": [\"28811495\", \"35393401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The C-terminal sequence of FGF21 defines its binding to β-Klotho (KLB) and is the primary determinant of receptor activation. C-terminal FGF21 peptides potently inhibit FGF21/KLB-mediated signaling. Key residues are highly conserved with FGF19, and substituting native FGF21 C-terminal sequence with an optimized high-affinity peptide generates a super-agonist with enhanced metabolic efficacy in obese mice.\",\n      \"method\": \"In vitro functional signaling assays, alanine-scanning mutagenesis of C-terminal peptides, KLB binding assays, in vivo obese mouse pharmacology\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis (Ala-scan), in vitro reconstitution assays, and in vivo validation in a single study\",\n      \"pmids\": [\"29789271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF21 structure was determined by NMR spectroscopy; the non-canonical flexible β-trefoil conformation affects folding of the β2-β3 hairpin and overall protein stability. A chimeric FGF21-FGF19 variant (FGF21SS) with modulated folding dynamics showed better thermostability, improved insulin sensitivity, and reduced blood glucose in ob/ob mice without inducing hepatocyte proliferation.\",\n      \"method\": \"NMR spectroscopy, chimeric protein design, thermostability assays, in vitro adipocyte insulin signaling assay, ob/ob mouse blood glucose and insulin measurement\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural determination by NMR with functional validation via mutagenesis/chimera and in vivo testing, single lab\",\n      \"pmids\": [\"33295692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pancreatitis is associated with loss of FGF21 expression in exocrine pancreas due to ISR activation inducing ATF3, a transcriptional repressor that directly binds specific sites on the Fgf21 promoter. FGF21 replacement mitigates ISR and resolves pancreatitis in three mouse models; ATF3 binding sites are conserved in human FGF21 promoter.\",\n      \"method\": \"ISR activation in cultured acinar cells and mouse pancreata, ATF3 chromatin immunoprecipitation on Fgf21 promoter, three mouse pancreatitis models, recombinant FGF21 pharmacological rescue, PERK inhibitor experiments, human pancreatitis tissue analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — promoter binding (ChIP), genetic and pharmacological models, human tissue validation, multiple mechanistic layers\",\n      \"pmids\": [\"31915301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FGF21 counteracts ethanol-induced intoxication by stimulating arousal via direct activation of noradrenergic neurons in the locus coeruleus, without changing ethanol catabolism. FGF21-deficient mice take longer to recover from ethanol; pharmacological FGF21 accelerates recovery. FGF21 does not counteract sedation by ketamine, diazepam, or pentobarbital, indicating ethanol specificity.\",\n      \"method\": \"FGF21 global knockout mice, pharmacological FGF21 administration, righting reflex and ataxia assays, locus coeruleus neuronal recording/activation studies, multiple sedative agent controls\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, pharmacological rescue, specificity controls, neuronal mechanism identified, published in Cell Metabolism\",\n      \"pmids\": [\"36889282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CNOT6L deadenylase controls FGF21 mRNA stability in hepatocytes. CNOT6L inhibition stabilizes Fgf21 mRNA, elevating serum FGF21 protein, which then acts on liver and adipose tissue to induce energy expenditure and lipid consumption. A small-molecule CNOT6L inhibitor that increases GDF15 and FGF21 improves diet-induced metabolic syndrome.\",\n      \"method\": \"CNOT6L inhibition (genetic and pharmacological), mRNA stability assays, serum hepatokine measurement, small-molecule screening, metabolic phenotyping in diet-induced obese mice\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mRNA stability mechanism defined, genetic and pharmacological interventions, small-molecule validation in vivo\",\n      \"pmids\": [\"35385705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF21 enhances adiponectin production, which in turn acts on cardiomyocytes (or FGF21 directly targets cardiomyocytes) to suppress PDK4 via PI3K/AKT signaling, thereby promoting mitochondrial bioenergetics and protecting against HFpEF. APN deletion abrogates FGF21's protective effects against HFpEF; genetic PDK4 inactivation mimics FGF21 protection.\",\n      \"method\": \"Global and adipose-specific FGF21 KO mice, HFD+L-NAME HFpEF model, FGF21 replenishment, adiponectin KO, PDK4 genetic inactivation, PI3K/AKT pathway assays, mitochondrial bioenergetics measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (FGF21 KO, adipose-specific KO, APN KO, PDK4 KO), defined PI3K/AKT/PDK4 signaling axis\",\n      \"pmids\": [\"39955281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Liver-derived FGF21 activates GABA-containing neurons expressing dopamine receptor 2 in the lateral hypothalamic area and zona incerta to mediate prolonged breastfeeding-induced protection against obesity, via enhanced BAT thermogenesis and energy expenditure. Tanycyte-controlled access to the hypothalamus gates FGF21 action.\",\n      \"method\": \"Delayed weaning rat model, transgenic mice, metabolic phenotyping, brain-specific pathway (tanycyte access), specific neuronal circuit identification (GABAergic DR2 neurons), hepatic FGF21 manipulation\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in-depth mechanistic dissection of neuronal circuit in multiple animal models, single published study\",\n      \"pmids\": [\"35879461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Central FGF21, produced not in the hypothalamus but in the retrosplenial cortex (RSC), enhances spatial memory by prolonging long-term potentiation in the hippocampus and activating hippocampal neurons, without regulating peripheral energy homeostasis or sugar intake.\",\n      \"method\": \"FGF21-Cre lineage tracing mouse model, RSC-specific FGF21 expression mapping, hippocampal LTP electrophysiology, spatial memory behavioral assays, energy homeostasis and sugar preference assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic lineage tracing identifying brain source, LTP electrophysiology, behavioral and metabolic phenotyping with clear dissociation of central vs. peripheral effects\",\n      \"pmids\": [\"36001982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PPARβ/δ deficiency in hepatocytes increases FGF21 expression via upregulation of the heme-regulated eIF2α kinase (HRI), which causes enhanced phospho-eIF2α and ATF4, driving Fgf21 transcription. siRNA knockdown confirmed HRI as a regulator of hepatic FGF21 expression, and pharmacological HRI activation increased FGF21 and reduced hepatic steatosis in an FGF21-dependent manner.\",\n      \"method\": \"PPARβ/δ knockout mice, siRNA knockdown of HRI and PPARβ/δ in primary hepatocytes, eIF2α and ATF4 western blotting, HRI pharmacological activator, Fgf21-null mice as controls\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — siRNA knockdown, genetic KO, pharmacological rescue, and FGF21-null validation in one study\",\n      \"pmids\": [\"27486236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Lactate rapidly induces FGF21 expression and secretion in adipocytes via a p38-MAPK-dependent, NADH/NAD-independent pathway. Pyruvate and ketone bodies similarly activate FGF21, suggesting sensing of intermediate metabolites drives adipose FGF21 release.\",\n      \"method\": \"Lactate treatment of adipocytes, pharmacological p38-MAPK inhibition, knockout mouse models, NADH/NAD manipulation, FGF21 mRNA and secretion assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection and genetic models, single lab\",\n      \"pmids\": [\"26769382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Metformin stimulates FGF21 expression in primary rat and human hepatocytes via AMPK activation; this effect is blocked by the AMPK inhibitor Compound C.\",\n      \"method\": \"Primary rat and human hepatocyte cultures, metformin treatment, AMPK inhibitor (Compound C), FGF21 mRNA and protein measurement\",\n      \"journal\": \"Experimental diabetes research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection in human primary cells, replicated in rat and human hepatocytes\",\n      \"pmids\": [\"23118742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Leptin increases FGF21 expression in vivo in rats and in HepG2 hepatocytes, and this effect is mediated by STAT3 activation.\",\n      \"method\": \"Leptin injection in Wistar rats, HepG2 cell treatment, STAT3 inhibition/activation, FGF21 mRNA/protein measurement\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell line (HepG2 hepatocarcinoma) and rat in vivo, limited mechanistic follow-up of STAT3 pathway\",\n      \"pmids\": [\"26982498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In MDCK mechanical cell competition, scribble-knockdown (scribKD) cells secrete FGF21 via the ASK1-p38 pathway, which attracts surrounding wild-type cells and drives their mechanical elimination of scribKD cells through FGFR1 signaling in wild-type cells.\",\n      \"method\": \"FGF21 knockdown in scribKD MDCK cells, FGFR1 loss-of-function in WT cells, conditioned medium cell motility assays, ASK1-p38 pathway pharmacology\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown of FGF21 and FGFR1 with mechanistic pathway dissection; novel cellular context (cell competition), single lab\",\n      \"pmids\": [\"33357449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FGF21 enhances BMP-2-induced osteogenesis by upregulating BMP-2-dependent Smad signaling (not p44/42 MAPK). BMP-2 in turn decreases endogenous FGF21 mRNA expression, forming a negative feedback loop.\",\n      \"method\": \"C2C12 cell osteogenic differentiation assay, alkaline phosphatase activity, matrix mineralization, Smad and MAPK phosphorylation western blotting, FGF21 mRNA measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single cell line model, single lab, no in vivo validation\",\n      \"pmids\": [\"23416071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF21 impedes peripheral nervous system myelin development by activating the p38 MAPK/c-Jun signaling axis in Schwann cells (not ERK). Anti-FGF21 antibody accelerates peripheral myelination in neonatal rats.\",\n      \"method\": \"Primary Schwann cell culture, recombinant FGF21 treatment, p38 MAPK and ERK pharmacological inhibition, gene knockdown, neonatal rat FGF21 injection, anti-FGF21 antibody infusion, myelin gene expression analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection plus in vivo injection and antibody blockade studies, single lab\",\n      \"pmids\": [\"32657446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF21 protects chondrocytes from apoptosis, senescence, and ECM catabolism by enhancing autophagy flux via TFEB nuclear translocation through activation of the SIRT1-mTOR signaling pathway, and reduces OA in a DMM mouse model.\",\n      \"method\": \"TBHP-induced chondrocyte stress model, FGF21 treatment, autophagy flux assay, TFEB nuclear translocation imaging, SIRT1-mTOR pathway western blotting, autophagy inhibitor (CQ), DMM mouse OA model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling pathway with pharmacological autophagy inhibition rescue, in vivo DMM model, single lab\",\n      \"pmids\": [\"34556628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF21 alleviates acute liver injury by enhancing SIRT1-mediated autophagy. Mechanistically, exogenous FGF21 upregulates LC3-II and Beclin1 (autophagy markers) via SIRT1 upregulation; SIRT1 knockdown by lentiviral RNAi reverses FGF21's hepatoprotective effect.\",\n      \"method\": \"CCl4-induced ALI mouse model, L02 hepatocyte cell line, FGF21 treatment, SIRT1 lentiviral RNAi knockdown in mice and cells, autophagy markers (LC3-II, Beclin1), ALT/AST/cytokine assays\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown reversal experiment in vivo and in vitro, defined SIRT1-autophagy mechanism, single lab\",\n      \"pmids\": [\"34984826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Excess BCAA decreases hepatic FGF21 production by inhibiting PPARα signaling; reduced FGF21 leads to higher cardiac LAT1 expression via transcription factor Zbtb7c, increasing cardiac BCAA uptake and mTOR-driven mitochondrial damage and apoptosis. Fecal microbiota transplant from healthy mice alleviated cardiac dysfunction in T1D mice, but this was abolished by FGF21 knockdown.\",\n      \"method\": \"T1D mouse model, gut microbiota BCAA profiling, FGF21 knockdown, PPARα signaling pathway assay, LAT1 and Zbtb7c expression, mTOR signaling, fecal microbiota transplant, cardiac function assays\",\n      \"journal\": \"Microbiome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FGF21 knockdown essential for pathway definition, multi-organ mechanistic dissection, single lab\",\n      \"pmids\": [\"39182099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FGF21 attenuates pulmonary arterial hypertension by suppressing miR-27b expression in HPAECs, which in turn de-represses PPARγ (a direct miR-27b target validated by luciferase assay), reducing NF-κB-driven inflammation and endothelial dysfunction.\",\n      \"method\": \"Hypoxia-induced HPAEC model, FGF21 treatment, miR-27b overexpression/inhibition, luciferase reporter assay for miR-27b/PPARγ targeting, NF-κB pathway assays, inflammatory cytokine measurement\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase validation of miR-27b/PPARγ targeting plus FGF21-mediated pathway, single lab, in vitro\",\n      \"pmids\": [\"33907846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF21 inhibits retinal and choroidal neovascularization, and this protective effect requires adiponectin (APN). FGF21 administration inhibited TNF-α but not VEGFA expression in neovascular eyes; APN-deficient mice were not protected by FGF21.\",\n      \"method\": \"Mouse oxygen-induced retinopathy model, VLDLR-deficient retinal angiomatous proliferation model, laser-induced choroidal neovascularization model, FGF21 administration, FGF21-KO, APN-KO mice, TNF-α and VEGFA measurement\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three independent neovascularization models, two genetic knockout models (FGF21-KO and APN-KO) identifying APN as essential mediator\",\n      \"pmids\": [\"28199833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF21 attenuates neuroinflammation after subarachnoid hemorrhage by promoting AMPK-dependent mitophagy in microglia, preventing mitochondrial DNA release and thereby suppressing cGAS-STING pathway activation. Conditional STING knockout in microglia ameliorated SAH-induced inflammation.\",\n      \"method\": \"SAH mouse model, recombinant FGF21 treatment, AMPK pharmacological manipulation, mitophagy assay, mtDNA cytoplasmic release measurement, cGAS-STING pathway assays, microglial STING conditional knockout, RNA sequencing, behavioral assays\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined AMPK-mitophagy-cGAS-STING mechanistic cascade with genetic STING KO validation, single lab\",\n      \"pmids\": [\"38720350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FGF21 has a direct pyrexic effect on body temperature that is independent of UCP1 and can occur without changes in energy expenditure. In UCP1-knockout mice, FGF21 increases body temperature by reducing heat loss (e.g., reduced tail surface temperature) rather than increasing heat production.\",\n      \"method\": \"UCP1-knockout mice, FGF21 administration at multiple ambient temperatures, indirect calorimetry, body temperature telemetry, tail surface temperature (infrared thermography), BAT temperature measurement\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic UCP1 KO with pharmacological FGF21, multiple temperature conditions, mechanistic dissection of pyrexia vs. hyperthermia\",\n      \"pmids\": [\"34418595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF21 effects on hepatic lipid metabolism and adiponectin secretion are sex-dependent. FGF21 reduced liver triglycerides and stimulated adiponectin via the adrenergic receptor→cAMP→EPAC signaling pathway in obese male mice but inhibited this pathway in females. Ovariectomized and reproductively senescent old females did not respond to FGF21 for liver TG or adiponectin, indicating the sex dependence is not mediated by an active female reproductive system.\",\n      \"method\": \"Male and female obese mouse models, FGF21 treatment, adiponectin measurement, adrenergic receptor-cAMP-EPAC pathway assays, ovariectomy model, aged female mice, liver triglyceride quantification\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sex-stratified analysis with surgical reproductive manipulation, defined adrenergic-cAMP-EPAC mechanism, single lab\",\n      \"pmids\": [\"35998055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PPARα-dependent DNA demethylation of the Fgf21 promoter in postnatal mouse liver regulates FGF21 gene expression. Targeted DNA demethylation using CRISPR/dCas9-TET1 at the Fgf21 promoter in PPARα-deficient mice restored fasting- and PPARα ligand-induced Fgf21 expression, providing direct evidence that DNA methylation status at the Fgf21 promoter determines the magnitude of gene expression response.\",\n      \"method\": \"CRISPR/dCas9-SunTag-scFv-TET1CD system, Fgf21 promoter-specific demethylation, Hepa1-6 cells, PPARα-deficient mice, bisulfite sequencing, PPARα agonist treatment, fasting experiment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — CRISPR epigenome editing with site-specific targeting, direct causal test of DNA methylation on FGF21 expression in vitro and in vivo\",\n      \"pmids\": [\"32198422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF21 reduces hypercholesterolaemia and atherosclerosis by promoting BAT activation and WAT browning, which enhances selective uptake of fatty acids from triglyceride-rich lipoproteins into thermogenic adipose tissues, accelerating clearance of cholesterol-enriched remnants by the liver.\",\n      \"method\": \"APOE*3-Leiden.CETP hypercholesterolaemic mouse model, pharmacological FGF21 administration, BAT activation measurement, WAT browning assessment, lipoprotein clearance assays, atherosclerotic lesion quantification, hepatic gene expression profiling\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined mechanistic pathway (BAT activation → TRL clearance → cholesterol reduction) with multiple metabolic readouts, single lab\",\n      \"pmids\": [\"33693480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF21 and PPARγ mutually promote each other's expression in pulmonary artery smooth muscle cells via the AMPK/PGC-1α pathway and the FGF21 co-receptor KLB, attenuating hypoxia-induced pulmonary hypertension.\",\n      \"method\": \"Hypoxia-induced pulmonary hypertension mouse model, FGF21 and PPARγ expression assays, AMPK/PGC-1α pathway analysis, KLB protein assay, in vitro and in vivo experiments\",\n      \"journal\": \"Experimental biology and medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway assays without rigorous genetic dissection, single lab, limited mechanistic validation\",\n      \"pmids\": [\"30714402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FGF21 inhibits FGF21 promoter via the FGFR-KLB-FGF21 autocrine axis to suppress CYP7A1 promoter activity in liver cells (hepatocyte autocrine mechanism). FGF21 protein directly inhibited CYP7A1 promoter activity in HepG2 cells, and this effect was mediated by conditioned medium from FGF21-overexpressing cells but not abolished by deletion of putative phosphorylated FGF21 effector response elements.\",\n      \"method\": \"HepG2 transfection with FGF21, luciferase reporter for CYP7A1 promoter, conditioned medium transfer, response element deletion mutants\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — luciferase reporter assay in hepatocarcinoma cell line, mechanism not fully resolved, single lab\",\n      \"pmids\": [\"29883717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF21 mediates MSC senescence via AMPK signaling that regulates mitochondrial dynamics (fusion/fission balance). FGF21 depletion in MSCs enhanced mitochondrial fusion (via Mfn2) and mitochondrial ROS, driving senescence; AMPK activation or Mfn2 knockdown abrogated FGF21-depletion-induced senescence.\",\n      \"method\": \"FGF21 siRNA depletion in MSCs, Mfn2 siRNA knockdown, AMPK activator (AICAR), mitochondrial morphology (MitoTracker), ROS measurement (MitoSox), SA-β-gal staining\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two genetic knockdowns and pharmacological AMPK activation with defined mechanistic pathway, single lab\",\n      \"pmids\": [\"31178962\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGF21 is a stress- and nutrient-responsive hepatokine (also produced by BAT, skeletal muscle, exocrine pancreas, and other tissues) that signals through a heterodimeric receptor complex of FGF receptor 1c (and other FGFRs) with the obligate co-receptor β-Klotho; it acts on adipose tissue (driving browning, UCP1-dependent thermogenesis, and glucose uptake), the brain (hypothalamus, locus coeruleus, and retrosplenial cortex for macronutrient preference, arousal, and memory), liver, and other organs to regulate glucose homeostasis, lipid oxidation, and energy expenditure—largely through downstream mediators including adiponectin (itself activating AMPK and PI3K/AKT signaling) and central noradrenergic circuits—with its transcription controlled by PPARα, ATF2/ATF4 via the integrated stress response, MyoD in muscle, and CREBH (degraded by HRD1-ERAD ubiquitination), and its mRNA stability regulated by the CNOT6L deadenylase.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGF21 is a stress- and nutrient-responsive endocrine factor secreted by multiple tissues—liver, brown adipose tissue, skeletal muscle, and exocrine pancreas—that signals through FGFR–β-Klotho (KLB) receptor complexes to coordinate systemic glucose homeostasis, lipid oxidation, thermoregulation, and central behavioral responses to diet [#1, #2, #4, #5, #7]. Its C-terminal sequence is the primary determinant of KLB binding and receptor activation, and its non-canonical flexible β-trefoil fold governs stability—features exploited to engineer super-agonist and chimeric variants with improved metabolic efficacy [#11, #12]. In the periphery, FGF21 acts largely through adiponectin: it raises adipocyte adiponectin secretion to mediate insulin sensitization, cardioprotection (suppressing cardiomyocyte PDK4 via PI3K/AKT), and inhibition of retinal/choroidal neovascularization, with these effects lost in adiponectin-null mice [#0, #16, #30]. FGF21 also drives glucose disposal through UCP1-dependent BAT thermogenesis, while a separate UCP1-independent pyrexic action raises body temperature by reducing heat loss [#9, #32]. In the brain, FGF21 signals through CNS β-Klotho to reduce sweet and alcohol preference, shift macronutrient preference during dietary protein restriction, and drive sympathetic outflow to BAT for thermoregulation; distinct circuits include locus coeruleus noradrenergic neurons (counteracting ethanol intoxication) and retrosplenial-cortex-derived FGF21 that enhances hippocampal LTP and spatial memory [#3, #5, #7, #14, #18]. FGF21 transcription is controlled by multiple inputs—PPARα (including PPARα-dependent promoter DNA demethylation), MyoD and ROS→p38→ATF2 in muscle, β-adrenergic/cAMP/PKA/p38/ATF2 in BAT, HRI→eIF2α→ATF4 in hepatocytes, and the integrated stress response acting through ATF3 (a repressor) in pancreas—while the CREBH transcription factor is gated by HRD1-ERAD ubiquitination and Fgf21 mRNA stability is set by the CNOT6L deadenylase [#1, #6, #8, #13, #15, #19, #34]. Dietary protein restriction extends lifespan and improves metabolic health in an FGF21-dependent manner [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that skeletal muscle is an FGF21 source and that PI3K/Akt1 signaling drives its muscle expression, broadening FGF21 beyond a liver-only hepatokine.\",\n      \"evidence\": \"Akt1 muscle-specific transgenic mice plus PI3K inhibition in cultured myocytes\",\n      \"pmids\": [\"18948104\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological stimulus driving muscle Akt1/FGF21 in vivo not defined\", \"Systemic role of muscle-derived FGF21 not isolated from liver source\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified BAT as a thermogenically activated FGF21 source and defined the β-adrenergic/cAMP/PKA/p38/ATF2 transcriptional pathway, linking sympathetic tone to FGF21 production.\",\n      \"evidence\": \"Arteriovenous difference across BAT, β-adrenergic pharmacology, p38 inhibition, ATF2 promoter binding, in vivo cold exposure\",\n      \"pmids\": [\"21317437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of BAT vs liver FGF21 to circulating pool not resolved here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined adiponectin as an obligatory downstream effector of FGF21's systemic insulin-sensitizing action, separating it from direct adipose ERK signaling.\",\n      \"evidence\": \"Adiponectin-knockout mice with FGF21 administration and metabolic readouts\",\n      \"pmids\": [\"23663741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which FGF21 induces adiponectin transcription not detailed\", \"Adiponectin-independent FGF21 actions not enumerated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed MyoD is the major muscle transcriptional regulator of FGF21 and that mitochondrial dysfunction induces FGF21 via ROS→p38→ATF2, casting FGF21 as a mitochondrial-stress signal.\",\n      \"evidence\": \"OXPHOS inhibitors, MyoD knockdown, ROS measurement, p38 inhibition, ATF2 promoter binding in muscle cells\",\n      \"pmids\": [\"25055037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo confirmation of MyoD requirement not shown\", \"Single-lab data\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated CNS β-Klotho-dependent FGF21 signaling reduces sweet and alcohol preference with reduced accumbal dopamine, establishing a central behavioral axis for FGF21.\",\n      \"evidence\": \"FGF21 administration in mice and monkeys, CNS-specific KLB knockout, accumbal dopamine measurement, preference assays\",\n      \"pmids\": [\"26724861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific neuronal targets and circuit not mapped here\", \"Link between dopamine change and preference is correlative\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Separated FGF21's weight-lowering effect from its glucose-clearance effect, showing the latter requires UCP1-dependent BAT thermogenesis.\",\n      \"evidence\": \"Ucp1-knockout mice with FGF21 administration, glucose tolerance tests, BAT temperature\",\n      \"pmids\": [\"26586424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How UCP1 thermogenesis mechanistically drives glucose disposal not detailed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Expanded transcriptional control of hepatic FGF21 to the HRI→eIF2α→ATF4 integrated-stress arm (de-repressed upon PPARβ/δ loss) and to AMPK (metformin), STAT3 (leptin), and metabolite sensing.\",\n      \"evidence\": \"PPARβ/δ KO mice and HRI siRNA with eIF2α/ATF4 readout; metformin/Compound C in hepatocytes; leptin/STAT3 in rats and HepG2; lactate/p38 in adipocytes\",\n      \"pmids\": [\"27486236\", \"23118742\", \"26982498\", \"26769382\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Leptin/STAT3 link is Low-confidence single cell line\", \"Integration of these inputs into a unified regulatory logic not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed an autocrine/paracrine FGF21 function in exocrine pancreas, stimulating digestive enzyme secretion via FGFR–β-Klotho and PLC-IP3R calcium signaling, with loss causing zymogen accumulation and ER stress.\",\n      \"evidence\": \"FGF21 and β-Klotho KO, acinar-specific KLB deletion, recombinant FGF21 rescue, calcium imaging, PLC-IP3R pharmacology\",\n      \"pmids\": [\"28089565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether circulating vs locally produced FGF21 dominates acinar action not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established FGF21 as essential for the lifespan-extending and metabolic benefits of dietary protein restriction, linking the hormone to healthy aging.\",\n      \"evidence\": \"FGF21 global knockout, long-term protein restriction, lifespan and frailty assessment\",\n      \"pmids\": [\"28811495\", \"35393401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue source and target circuit mediating longevity effect not isolated here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined upstream control of FGF21 production by HRD1-ERAD ubiquitination of the ER-tethered transcription factor CREBH at K294, coupling nutrient state (refeeding) to FGF21 suppression.\",\n      \"evidence\": \"Liver-specific HRD1 KO, in vitro ubiquitination with K294 mutagenesis, proteasome inhibition, refeeding\",\n      \"pmids\": [\"30389664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal triggering CREBH activation versus degradation balance not fully mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped the C-terminal sequence as the primary KLB-binding/receptor-activation determinant, enabling antagonist peptides and engineered super-agonists.\",\n      \"evidence\": \"In vitro signaling assays, alanine-scanning mutagenesis, KLB binding assays, obese mouse pharmacology\",\n      \"pmids\": [\"29789271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the C-terminus–KLB contact not solved here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed brain KLB signaling, not direct adipose action, mediates the adaptive response to protein restriction (macronutrient preference, energy expenditure, glucose), centralizing FGF21's site of action.\",\n      \"evidence\": \"Brain-specific KLB KO and whole-body FGF21 KO with protein restriction phenotyping\",\n      \"pmids\": [\"31167139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific brain neuronal population not identified in this study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated liver, not adipose, is the cold-induced circulating FGF21 source, and central KLB signaling drives sympathetic BAT activation while adipose-direct FGF21 signaling is dispensable for thermoregulation.\",\n      \"evidence\": \"Liver-, adipose-, and adipose-KLB-specific KO mice, CNS FGF21 blockade, cold exposure, temperature monitoring\",\n      \"pmids\": [\"30679672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of CNS thermoregulatory FGF21-target neurons not defined here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Solved the FGF21 NMR structure, attributing its instability to a non-canonical flexible β-trefoil and engineering a folding-stabilized chimera with better glycemic efficacy and no mitogenic effect.\",\n      \"evidence\": \"NMR spectroscopy, chimera design, thermostability assays, ob/ob mouse glucose/insulin\",\n      \"pmids\": [\"33295692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-bound structure not determined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Added PPARα-dependent Fgf21 promoter DNA demethylation as a determinant of FGF21 expression magnitude, demonstrated causally by targeted dCas9-TET1 demethylation.\",\n      \"evidence\": \"CRISPR/dCas9-TET1 epigenome editing at the Fgf21 promoter in PPARα-deficient mice and Hepa1-6 cells, bisulfite sequencing\",\n      \"pmids\": [\"32198422\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Developmental timing and enzymes setting methylation not fully defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified ATF3 as an integrated-stress-response repressor that directly silences the Fgf21 promoter in pancreatitis, with FGF21 replacement resolving disease and conserved human ATF3 sites.\",\n      \"evidence\": \"ATF3 ChIP on Fgf21 promoter, three pancreatitis mouse models, recombinant FGF21 rescue, PERK inhibition, human tissue\",\n      \"pmids\": [\"31915301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ATF3 repression operates in other FGF21-producing tissues not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Dissociated FGF21's pyrexic action from thermogenesis, showing a UCP1-independent rise in body temperature achieved by reducing heat loss.\",\n      \"evidence\": \"UCP1-KO mice, FGF21 across ambient temperatures, calorimetry, telemetry, tail thermography\",\n      \"pmids\": [\"34418595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effector mechanism for reduced heat loss (e.g. vasomotor control) not specified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined CNOT6L deadenylase as a post-transcriptional brake on Fgf21 mRNA stability, providing a druggable node to raise circulating FGF21.\",\n      \"evidence\": \"Genetic and pharmacological CNOT6L inhibition, mRNA stability assays, small-molecule validation in diet-induced obese mice\",\n      \"pmids\": [\"35385705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specificity of CNOT6L for Fgf21 versus other transcripts not bounded\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved central FGF21 circuit diversity: liver-derived FGF21 acts on hypothalamic GABAergic DR2 neurons (gated by tanycytes) for breastfeeding-induced obesity protection, while RSC-derived FGF21 enhances hippocampal LTP and spatial memory independent of energy homeostasis.\",\n      \"evidence\": \"FGF21-Cre lineage tracing, RSC mapping, hippocampal LTP electrophysiology, delayed-weaning models, behavioral and metabolic assays\",\n      \"pmids\": [\"35879461\", \"36001982\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RSC-derived FGF21 source mechanism is Medium-confidence single study for the hypothalamic circuit\", \"How distinct FGF21 sources access separate circuits not unified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended the FGF21–adiponectin axis to cardioprotection, showing it suppresses cardiomyocyte PDK4 via PI3K/AKT to preserve mitochondrial bioenergetics in HFpEF, and revealed sex-dependent adrenergic-cAMP-EPAC control of adiponectin/hepatic lipid responses.\",\n      \"evidence\": \"FGF21, adipose-specific FGF21, adiponectin and PDK4 KO mice in HFpEF; sex-stratified obese models with ovariectomy and adrenergic-cAMP-EPAC assays\",\n      \"pmids\": [\"39955281\", \"35998055\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether cardiac protection is via circulating adiponectin or direct cardiomyocyte FGF21 not fully separated\", \"Molecular basis of sex divergence in EPAC signaling unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified locus coeruleus noradrenergic neurons as the substrate by which FGF21 counteracts ethanol intoxication through arousal, with specificity for ethanol over other sedatives.\",\n      \"evidence\": \"FGF21 KO and pharmacological rescue, righting/ataxia assays, LC neuronal activation, sedative-agent controls\",\n      \"pmids\": [\"36889282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and intracellular pathway in LC neurons not detailed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse upstream transcriptional, epigenetic, and post-transcriptional inputs and the multiple tissue sources are integrated to set context-specific FGF21 output, and how distinct central circuits are selectively engaged, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking source tissue to specific peripheral/central target\", \"Receptor-level structural basis of KLB engagement in each tissue not solved\", \"Many disease-context mechanisms (atherosclerosis, OA, neuroinflammation, PAH) rest on single-lab studies\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [4, 11, 0]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 2, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 9, 16, 35]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 7, 4]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 8, 13, 19, 34]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [14, 18, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"KLB\", \"FGFR1\", \"ADIPOQ\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}